The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)'s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to ...

A back-of-the-envelope comparison puts MariTide with a slightly better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below market ...

After 12 weeks, weight loss with the drug was 13% of body weight ... pain and physical function in the STEP 9 trial. Lilly's Zepbound has become the first drug approved by the FDA for obese ...